Interestingly, our research indicated that CD58 might act as an immune checkpoint gene in HCC and regulate the levels of tumor-infiltrating immune cells in HCC tissues, which might be an immunotherapeutic target in HCC. This evidence concerns the gene CD58 and hepatocellular carcinoma.